Scrip

Sosei Heptares Adds Lilly To Big Pharma Client List

Inks Diabetes And Metabolic Diseases Deal

16 Dec 2022

The Japan-UK group is ending the year on a high, banking $37m upfront from a pact with Eli Lilly that will focus on finding small molecules which modulate G protein-coupled receptor (GPCR) targets.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal. — • Source: Shutterstock

Sosei Heptares has added Eli Lilly and Company to its lengthy list of big pharma partners with the signing of a potentially lucrative metabolic disease pact.